Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Julie R. Brahmer, Melissa Lynne Johnson, Manuel Cobo Dols, Santiago Viteri Ramirez, Juan Coves, Ammar Sukari, Mark M. Awad, Ravi Salgia, Vassiliki Papadimitrakopoulou, Arun Rajan, Alicia Jones Allred, Mark Wade, Gary Mason, Enrique Zudaire, Roland Elmar Knoblauch, Nicole L. Stone, Matthew V. Lorenzi, Raffit Hassan
Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Sarah Cannon, Hospital Regional Universitario de Málaga, Instituto Oncológico Dr. Rosell, Hospital Universitario Dexeus, Hospital Son Llatzer, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute, City Of Hope National Medical Center, City of Hope, The University of Texas MD Anderson Cancer Center, National Institutes of Health, National Cancer Institute, Center for Cancer Research, Janssen Research & Development (United States)
Language: English
Subfield: Biotechnology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2963537368